Key result
Redo TEER lacks sufficient evidence to define its clinical role for recurrent mitral regurgitation.
Why the study?
Does redo-TEER improve clinical outcomes in patients with recurrent mitral regurgitation after initial TEER?
Does redo-TEER improve clinical outcomes in patients with recurrent mitral regurgitation after initial TEER?
The role and clinical outcomes of redo-TEER for recurrent mitral regurgitation remain insufficiently defined and require further investigation.
Recurrent mitral regurgitation (MR) after transcatheter edge-to-edge repair (TEER) is increasingly encountered, with limited evidence to guide management. The role of redo-TEER remains insufficiently defined.
No takes yet. Share an insight, caveat, or question.
Moroni et al. (2026) studied this question. Redo transcatheter edge-to-edge repair (TEER) for recurrent mitral regurgitation currently lacks sufficient evidence to clearly define its clinical role and guide management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: